N-terminal pro brain natriuretic peptide: The new cornerstone of cardiovascular assessment in systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 27, Issue 3 SUPPL. 54, 2009, Pages

  Allanore, Yannick ^a   Meune, Christophe ^a  

^a Paris Descartes University ^*  (France)

Author keywords

Cardiac involvement; Myocardium; Natriuretic peptides; Pulmonary arterial hypertension; Systemic sclerosis; Tissue Doppler echocardiography

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

AORTA VALVE REGURGITATION; CARDIOVASCULAR DISEASE; CONGENITAL HEART MALFORMATION; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DOPPLER ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE PERFUSION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICULOGRAPHY; HUMAN; LUNG ARTERY PRESSURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERICARDIAL EFFUSION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; TISSUE DOPPLER IMAGING;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COMORBIDITY; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN PRECURSORS; SCLERODERMA, SYSTEMIC;

EID: 70350314390     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. KAHAN A, ALLANORE Y: Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford) 2006; 45 (Suppl. 4): iv14-iv17.
2. KARASSA FB, IOANNIDIS JP: Mortality in systemic sclerosis. Clin Exp Rheumatol 2008; 26 (Suppl. 51): S85-93.
3. MEUNE C, ALLANORE Y, VIGNAUX O et al.: Predominant primitive right ventricular involvement in systemic sclerosis. Clin Exp Rheumatol 2007; 25: 658. (Pubitemid 47455478)
4. FERRI C, VALENTINI G, COZZI F et al.: Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81: 139-153
5. ALLANORE Y, MEUNE C, VONK MC et al.: Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of systemic sclerosis patients. Ann Rheum Dis 2009 Mar 10. [Epub ahead of print].
6. PERERA A, FERTIG N, LUCAS M et al.: Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 2007; 56: 2740-2746
7. IOANNIDIS JP, VLACHOYIANNOPOULOS PG, HAIDICH AB et al.: Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118: 2-10. (Pubitemid 40082450)
8. CZIRJÁK L, KUMÁNOVICS G, VARJÚ C et al.: Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008; 67: 59-63.
9. CONDLIFFE R, KIELY DG, PEACOK AJ et al.: Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-157
10. FISHER MR, MATHAI SC, CHAMPION SC et al.: Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54: 3043-3050
11. MEUNE C, AVOUAC J, WAHBI K et al.: Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients. Arthritis Rheum 2008; 58: 1803-1809
12. DE GROOTE P, GRESSIN V, HACHULLA E et al.: Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008; 67: 31-36
13. HANDA R, GUPTA K, MALHOTRA A et al.: Cardiac involvement in limited systemic sclerosis: non-invasive assessment in asymptomatic patients. Clin Rheumatol 1999; 18: 136-139
14. MAIONE S, CUOMO G, GIUNTA A et al.: Echocardiographic alterations in systemic sclerosis: a longitudinal study. Semin Arthritis Rheum 2005; 34: 721-727 (Pubitemid 40501508)
15. FOLLANSBEE WP, CURTISS EI, MEDSGER TA JR et al.: Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med 1984; 310: 142-148
16. MEUNE C, ALLANORE Y, PASCAL O et al.: Myocardial contractility is early affected in systemic sclerosis: a tissue Doppler echocardiography study. Eur J Echocardiography 2005; 6: 351-357
17. ALLANORE Y, MEUNE C, VIGNAUX O, WEBER S, LEGMANN P, KAHAN A: Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. J Rheumatol 2006; 33: 2464-2469
18. MUKERJEE D, ST GEORGE D, COLEIRO B et al.: Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-1093
19. HACHULLA E, GRESSIN V, GUILLEVIN L et al.: Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792-3800
20. VONK MC, BROERS B, HEIJDRA YF et al.: Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study. Ann Rheum Dis 2009; 68: 961-965
21. FERRI C, EMDIN M, NIELSEN H, BRUHLMANN P: Assessment of heart involvement. Clin Exp Rheumatol 2003; 21 (Suppl. 29): S24-8.
22. VALENTINI G, MATUCCI CERINIC M: Disease-specific quality indicators, guidelines and outcome measures in scleroderma. Clin Exp Rheumatol 2007; 25 (Suppl. 47): 159-162
23. D'ANDREA A, STISI S, BELLISIMO S et al.: Early impairment of myocardial function in systemic sclerosis: non-invasive assessment by Doppler myocardial and strain rate imaging. Eur J Echocardiogr 2005; 6: 407-418
24. TZELEPIS GE, KELEKIS NL, PLASTIRAS SC et al.: Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum 2007; 56: 3827-3836
25. BEZANTE GP, ROLLANDO D, SESSAREGO M et al.: Cardiac magnetic resonance imaging detects subclinical right ventricular impairment in systemic sclerosis. J Rheumatol 2007; 34: 2431-2437
26. MCCANN GP, GAN CT, BEEK AM, NIESSEN HW, VONK NOORDEGRAAF A, VAN ROSSUM AC: Extent of MRI delayed enhancement of myocardial mass is related to right ventricular dysfunction in pulmonary artery hypertension. AJR Am J Roentgenol 2007; 188: 349-355
27. DANIELS LB, MAISEL AS: Natriuretic peptides. J Am Coll Cardiol 2007; 50: 2357-68.
28. MARTINEZ-RUMAYOR A, RICHARDS AM, BURNETT JC, JANUZZI JL JR: Biology of the natriuretic peptides. Am J Cardiol 2008; 101: 3-8.
29. MAISEL A, MUELLER C, ADAMS K JR et al.: State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824-839
30. SOUZA R, JARDIM C, JULIO CESAR FERNANDES C, SILVEIRA LAPA M, RABELO R, HUMBERT M: NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respir Med 2007; 101: 69-75.
31. LEUCHTE HH, HOLZAPFEL M, BAUMGARTNER RA, NEUROHR C, VOGESER M, BEHR J: Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest 2005; 128: 2368-74.
32. ANDREASSEN AK, WERGELAND R, SIMONSEN S, GEIRAN O, GUEVARA C, UELAND T: N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 2006; 98: 525-529
33. NAGAYA N, NISHIKIMI T, UEMATSU M et al.: Plasma Brain Natriuretic Peptide as a Prognostic Indicator in Patients With Primary Pulmonary Hypertension. Circulation 2000; 102: 865-870
34. ALLANORE Y, BORDERIE D, MEUNE C et al.: NT-pro-B-type brain natriuretic peptide as a diagnostic marker of early pulmonary arterial hypertension and effects of calcium channel blockers in systemic sclerosis. Arthritis Rheum 2003; 48: 3503-3508
35. WILLIAMS MH, AKRAM R, SMITH CJ et al.: Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27: 1485-1494 (Pubitemid 43998084)
36. SIMEONI S, LIPPI G, PUCCETTI A et al.: N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int 2008; 28: 657-660
37. DIMITROULAS T, GIANNAKOULAS G, KARVOUNIS H et at.: N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clin Rheumatol 2008; 27: 655-658
38. ALLANORE Y, BORDERIE D, AVOUAC J et al.: High NT-pro brain natriuretic peptide and low carbon monoxide lung diffusion capacity are independent predictors of the occurrence of pre-capillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008; 58: 284-291
39. ALLANORE Y, WAHBI K, BORDERIE D, WEBER S, KAHAN A, MEUNE C: N-terminal brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment? Ann Rheum Dis 2008 Dec 3. [Epub ahead of print].